Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.
Stephen Opat, MBBS
Advertisement
Stephen Opat, MBBS, is the director of Clinical Hematology at Monash Health, Monash University; founder and chair of the Australasian Lymphoma and Related Diseases Registry; and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship in Australia.
Articles by Stephen Opat, MBBS
Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
BGB-11417-101 is a global phase 1/1b study evaluating sonrotoclax as monotherapy, or in combination ± zanubrutinib, and ± obinutuzumab in patients with B-cell malignancies. (NCT04277637)
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5